




Biotech-Pharma (Therapy)

Compositions for the treatment, relief and/or ophthalmologic pathologies, such as blepharitis and dry eye syndrome.

A research group from the Andalusian Public Health System (SSPA) has developed a composition based on doxycycline, as well as a solution to be used for the relief, improvement, prevention and/or treatment of dry eye syndrome.



Description

Both blepharitis and dry eye syndrome are the most common diseases in ophthalmology and currently there are no effective solutions for its prevention and treatment.

The research group has developed the following two compositions that provide a solution to the above mentioned pathologies.

First part of this invention is related to the use of a composition of doxycycline for prevention, improvement and/or treatment of blepharitis, microthrombosis in the anterior pole and chorioretinal vascular disorders.

Second part of the invention is related to the use of a composition from different plants for the manufacture of a medicament for the alleviation, improvement, prevention and/or treatment of eye diseases, preferably for the treatment of dry eye syndrome.



Advantages

Regarding the doxycycline based composition for the treatment of ophthalmologic pathologies, the following advantages should be highlighted:

- Anti-infective.
- Anti-inflammatory.
- It improves the **efficiency (high bioavailability)**, when compared with standard antibiotics.
- It **reduces the adverse effects**, typically produced by anti-inflammatories medicines.

The composition for the treatment of dry eye syndrome provides epithelializing, antibacterial, antifungal, astringent and anti-inflammatory effects in addition to following advantages:

- **Cheap manufacturing** production process.
- Easy dispensation.
- Based on **natural products**.
- It allows continuous use and has **no side effects**.



Intellectual Property

This technology is protected by Patent Application (PCT).



Objectives

The group is looking for a partner interested in a license and/or a collaboration agreement to further develop and exploit this innovative technology.



Classification

Area: Biotech-Pharma (Therapy)
Pathology: dry eye syndrome, blepharitis.
Keywords: dry eye syndrome, blepharitis.